LENSAR’s (LNSR) Hold Rating Reiterated at Lake Street Capital

Lake Street Capital reiterated their hold rating on shares of LENSAR (NASDAQ:LNSR) in a research report report published on Monday, Marketbeat reports. They currently have a $15.00 price target on the stock, down from their previous price target of $16.00.

LENSAR Stock Performance

LNSR stock opened at $14.14 on Monday. LENSAR has a one year low of $2.67 and a one year high of $17.31. The firm has a market cap of $166.70 million, a price-to-earnings ratio of -9.68 and a beta of 0.62. The firm has a 50-day simple moving average of $11.81 and a two-hundred day simple moving average of $8.36.

LENSAR (NASDAQ:LNSR) last posted its earnings results on Thursday, February 27th. The company reported ($1.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.40). LENSAR had a negative net margin of 34.03% and a negative return on equity of 49.02%. The firm had revenue of $16.73 million for the quarter, compared to analysts’ expectations of $14.95 million.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its holdings in LENSAR by 3.5% in the third quarter. Geode Capital Management LLC now owns 100,431 shares of the company’s stock worth $460,000 after acquiring an additional 3,423 shares in the last quarter. Atria Investments Inc raised its position in shares of LENSAR by 28.2% in the 4th quarter. Atria Investments Inc now owns 26,055 shares of the company’s stock valued at $233,000 after purchasing an additional 5,729 shares during the last quarter. Essex Investment Management Co. LLC boosted its stake in LENSAR by 18.3% in the 4th quarter. Essex Investment Management Co. LLC now owns 39,890 shares of the company’s stock worth $357,000 after purchasing an additional 6,184 shares in the last quarter. Evernest Financial Advisors LLC purchased a new stake in LENSAR during the 4th quarter worth approximately $174,000. Finally, Bailard Inc. purchased a new stake in LENSAR during the 4th quarter worth approximately $181,000. 40.15% of the stock is owned by institutional investors and hedge funds.

LENSAR Company Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.